Like other human pathogenic viruses, coronavirus SARS-CoV-2 employs sophisticated macromolecular
machines for viral host cell entry, genome replication and protein processing. Such machinery
encompasses SARS-CoV-2 envelope spike (S) glycoprotein required for host cell entry by binding
to the ACE2 receptor, viral RNA-dependent RNA polymerase (RdRp) and 3-chymotrypsin-like main
protease (3Clpro/Mpro). Under the pressure of the accelerating COVID-19 pandemic caused by the outbreak
of SARS-CoV-2 in Wuhan, China in December 2019, novel and repurposed drugs were recently
designed and identified for targeting the SARS-CoV-2 reproduction machinery, with the aim to limit the
spread of SARS-CoV-2 and morbidity and mortality due to the COVID-19 pandemic.
Keywords: Coronavirus SARS-CoV-2, COVID-19, S protein, RNA polymerase, 3Clpro, Camostat, Remdesivir, α-Ketoamides.
Rights & PermissionsPrintExport